Sanz Morales, P.
ORCID: https://orcid.org/0000-0002-0719-2282, Wijeyesekera, A.
ORCID: https://orcid.org/0000-0001-6151-5065, Robertson, M. D., Major, G., Boulangé, C. L., Jackson, P. P. J.
ORCID: https://orcid.org/0000-0003-0098-4719, Poveda Turrado, C. G. and Gibson, G. R.
ORCID: https://orcid.org/0000-0002-0566-0476
(2025)
An in vitro batch culture study to assess the fermentation of human milk oligosaccharides by faecal microbiota from healthy and irritable bowel syndrome stool donors.
Gut Microbiome, 6.
e4.
ISSN 2632-2897
Preview |
Text (Open Access)
- Published Version
· Available under License Creative Commons Attribution. · Please see our End User Agreement before downloading. 1MB |
It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.
To link to this item DOI: 10.1017/gmb.2025.2
Abstract/Summary
Abstract This study explored the effects of different human milk oligosaccharides (HMOs), solely and in combination, on gut microbiota composition and metabolic activity (organic acid production), using anaerobic in vitro batch culture fermenters. The aim was to compare prebiotic effects of HMOs (2’FL, 3’FL, 3’SL, 6’SL, LNT, LNnT, and 1:1 ratio mixes of 2’FL/3’SL and 3’SL/LNT) in faecal samples from irritable bowel syndrome (IBS) donors and healthy controls, and to determine the best-performing HMO in IBS. Fluorescent in situ hybridisation coupled with flow cytometry was utilised to study microbiota changes in major colonic genera, and organic acid production was assessed by gas chromatography. IBS donors had different starting microbial profiles compared to healthy controls and lower levels of organic acids. In response to HMOs, there were alterations in both the control and IBS faecal microbiomes. In IBS donor fermenters, Bifidobacterium , Faecalibacterium , total bacterial numbers, and organic acid production significantly increased post-HMO intervention. When comparing the effect of HMO interventions on the microbiota and organic acid production, a mix of 3’SL/LNT HMOs may be the most promising intervention for IBS patients.
| Item Type: | Article |
|---|---|
| Refereed: | Yes |
| Divisions: | Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Food Microbial Sciences Research Group |
| ID Code: | 122697 |
| Publisher: | Cambridge University Press |
Downloads
Downloads per month over past year
University Staff: Request a correction | Centaur Editors: Update this record
Lists
Lists